ROCK inhibitors as emerging therapeutic candidates for sarcomas

Current Cancer Drug Targets

Volumn 10, Issue 2, 2010, Pages 127-134

  Micuda S ^a   Rosel D ^a   Ryska A ^a   Brabek J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Invasiveness; Rho; ROCK; Sarcoma

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; AMINOFURAZAN DERIVATIVE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CHROMAN 3 AMIDE DERIVATIVE; CISPLATIN; DOXORUBICIN; FASUDIL; GEMCITABINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; INDAZOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; PACLITAXEL; RHO KINASE INHIBITOR; RISEDRONIC ACID; UNCLASSIFIED DRUG; VASODILATOR AGENT; WF 536; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; ASTHMA; BREAST CANCER; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER INVASION; CARCINOMA CELL; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHOLESTASIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CORONARY ARTERY SPASM; DIABETIC NEPHROPATHY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY INJURY; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG INJURY; LUNG METASTASIS; MELANOMA CELL; METASTASIS INHIBITION; METASTASIS POTENTIAL; NONHUMAN; OSTEOPOROSIS; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; PULMONARY HYPERTENSION; REVIEW; SARCOMA; SARCOMA CELL; SIGNAL TRANSDUCTION; STABLE ANGINA PECTORIS; SUBARACHNOID HEMORRHAGE;

CELL ADHESION; CELL MOVEMENT; HUMANS; PROTEASE INHIBITORS; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; SARCOMA; SIGNAL TRANSDUCTION;

EID: 77950667079     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800910791054202     Document Type: Review

References (92)

1. Pokorna, E.; Zicha, D.; Chaloupkova, A.; Matouskova, E.; Vesely, P. Two dynamic morphotypes of sarcoma cells, asymmetric stellate and triangle with leading lamella, are related to malignancy. Folia Biol. (Praha) 2003, 49, 33-39.
2. Lambert, R. A.; Hanes, F. M. Characteristics of growth of sarcoma and carcinoma cultivated in vitro. J. Exp. Med. 1911, 13, 495-504.
3. Hogue, M. J.; Rubin, A. Studies on the solid form of mouse sarcoma 37 grown in tissue culture. Cancer Res. 1955, 15, 462-463.
4. Ozzello, L.; Stout, A. P.; Murray, M. R. Cultural characteristics of malignant histiocytomas and fibrous xanthomas. Cancer 1963, 16, 331-344.
5. O'Brien, J. E.; Stout, A. P. Malignant fibrous xanthomas. Cancer 1964, 17, 1445-1455.
6. Abercrombie, M.; Ambrose, E. J. Interference microscope studies of cell contacts in tissue culture. Exp. Cell Res. 1958, 15, 332-345.
7. Bottino, D. C.; Fauci, L. J. A computational model of ameboid deformation and locomotion. Eur. Biophys. J. 1998, 27, 532-539.
8. Sahai, E.; Marshall, C. J. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat. Cell Biol. 2003, 5, 711-719.
9. Wolf, K.; Mazo, I.; Leung, H.; Engelke, K.; von Andrian, U. H.; Deryugina, E. I.; Strongin, A. Y.; Brocker, E. B.; Friedl, P. Compensation mechanism in tumor cell migration: mesenchymalamoeboid transition after blocking of pericellular proteolysis. J. Cell Biol. 2003, 160, 267-277.
10. Wyckoff, J. B.; Pinner, S. E.; Gschmeissner, S.; Condeelis, J. S.; Sahai, E. ROCK- and myosin-dependent matrix deformation enables protease-independent tumor-cell invasion in vivo . Curr. Biol. 2006, 16, 1515-1523.
11. Rosel, D.; Brabek, J.; Tolde, O.; Mierke, C. T.; Zitterbart, D. P.; Raupach, C.; Bicanova, K.; Kollmannsberger, P.; Pankova, D.; Vesely, P.; Folk, P.; Fabry, B. Up-regulation of Rho/ROCK signaling in sarcoma cells drives invasion and increased generation of protrusive forces. Mol. Cancer Res. 2008, 6, 1410-1420.
12. Pankova, K.; Rosel, D.; Novotny, M.; Brabek, J. The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cells. Cell Mol. Life Sci. 2010, 67, 63-71.
13. Mierke, C. T.; Rosel, D.; Fabry, B.; Brabek, J. Contractile forces in tumor cell migration. Eur. J. Cell Biol. 2008, 87, 669-676.
14. Yee, H. F., Jr.; Melton, A. C.; Tran, B. N. RhoA/rho-associated kinase mediates fibroblast contractile force generation. Biochem. Biophys. Res. Commun. 2001, 280, 1340-1345.
15. Zhao, Z. S.; Manser, E. PAK and other Rho-associated kinases - effectors with surprisingly diverse mechanisms of regulation. Biochem. J. 2005, 386, 201-214.
16. Ishizaki, T.; Maekawa, M.; Fujisawa, K.; Okawa, K.; Iwamatsu, A.; Fujita, A.; Watanabe, N.; Saito, Y.; Kakizuka, A.; Morii, N.; Narumiya, S. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J. 1996, 15, 1885-1893.
17. Sahai, E.; Marshall, C. J. ROCK and Dia have opposing effects on adherens junctions downstream of Rho. Nat. Cell Biol. 2002, 4, 408-415.
18. Ito, M.; Nakano, T.; Erdodi, F.; Hartshorne, D. J. Myosin phosphatase: structure, regulation and function. Mol. Cell Biochem. 2004, 259, 197-209.
19. Amano, M.; Ito, M.; Kimura, K.; Fukata, Y.; Chihara, K.; Nakano, T.; Matsuura, Y.; Kaibuchi, K. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J. Biol. Chem. 1996, 271, 20246-20249.
20. Totsukawa, G.; Yamakita, Y.; Yamashiro, S.; Hartshorne, D. J.; Sasaki, Y.; Matsumura, F. Distinct roles of ROCK (Rho-kinase) and MLCK in spatial regulation of MLC phosphorylation for assembly of stress fibers and focal adhesions in 3T3 fibroblasts. J. Cell Biol. 2000, 150, 797-806.
21. Tumusiime, S.; Rana, M. K.; Kher, S. S.; Kurella, V. B.; Williams, K. A.; Guidry, J. J.; Worthylake, D. K.; Worthylake, R. A. Regulation of ROCKII by localization to membrane compartments and binding to DynaminI. Biochem. Biophys. Res. Commun. 2009, 381, 393-396.
22. Totsukawa, G.; Wu, Y.; Sasaki, Y.; Hartshorne, D. J.; Yamakita, Y.; Yamashiro, S.; Matsumura, F. Distinct roles of MLCK and ROCK in the regulation of membrane protrusions and focal adhesion dynamics during cell migration of fibroblasts. J. Cell Biol. 2004, 164, 427-439.
23. Velasco, G.; Armstrong, C.; Morrice, N.; Frame, S.; Cohen, P. Phosphorylation of the regulatory subunit of smooth muscle protein phosphatase 1M at Thr850 induces its dissociation from myosin. FEBS Lett. 2002, 527, 101-104.
24. Tan, I.; Ng, C. H.; Lim, L.; Leung, T. Phosphorylation of a novel myosin binding subunit of protein phosphatase 1 reveals a conserved mechanism in the regulation of actin cytoskeleton. J. Biol. Chem. 2001, 276, 21209-21216.
25. Hagerty, L.; Weitzel, D. H.; Chambers, J.; Fortner, C. N.; Brush, M. H.; Loiselle, D.; Hosoya, H.; Haystead, T. A. ROCK1 phosphorylates and activates zipper-interacting protein kinase. J. Biol. Chem. 2007, 282, 4884-4893.
26. Sanders, L. C.; Matsumura, F.; Bokoch, G. M.; de Lanerolle, P. Inhibition of myosin light chain kinase by p21-activated kinase. Science 1999, 283, 2083-2085.
27. Leung, T.; Chen, X. Q.; Tan, I.; Manser, E.; Lim, L. Myotonic dystrophy kinase-related Cdc42-binding kinase acts as a Cdc42 effector in promoting cytoskeletal reorganization. Mol. Cell Biol. 1998, 18, 130-140.
28. Kimura, K.; Ito, M.; Amano, M.; Chihara, K.; Fukata, Y.; Nakafuku, M.; Yamamori, B.; Feng, J.; Nakano, T.; Okawa, K.; Iwamatsu, A.; Kaibuchi, K. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 1996, 273, 245-248.
29. Wilkinson, S.; Paterson, H. F.; Marshall, C. J. Cdc42-MRCK and Rho-ROCK signalling cooperate in myosin phosphorylation and cell invasion. Nat. Cell Biol. 2005, 7, 255-261.
30. Manser, E.; Chong, C.; Zhao, Z. S.; Leung, T.; Michael, G.; Hall, C.; Lim, L. Molecular cloning of a new member of the p21-Cdc42/Rac-activated kinase (PAK) family. J. Biol. Chem. 1995, 270, 25070-25078.
31. Murthy, K. S.; Zhou, H.; Grider, J. R.; Brautigan, D. L.; Eto, M.; Makhlouf, G. M. Differential signalling by muscarinic receptors in smooth muscle: m2-mediated inactivation of myosin light chain kinase via Gi3, Cdc42/Rac1 and p21-activated kinase 1 pathway, and m3-mediated MLC20 (20 kDa regulatory light chain of myosin II) phosphorylation via Rho-associated kinase/myosin phosphatase targeting subunit 1 and protein kinase C/CPI-17 pathway. Biochem. J. 2003, 374, 145-155.
32. Belletti, B.; Nicoloso, M. S.; Schiappacassi, M.; Berton, S.; Lovat, F.; Wolf, K.; Canzonieri, V.; D'Andrea, S.; Zucchetto, A.; Friedl, P.; Colombatti, A.; Baldassarre, G. Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. Mol. Biol. Cell 2008, 19, 2003-2013.
33. Palazzo, A. F.; Eng, C. H.; Schlaepfer, D. D.; Marcantonio, E. E.; Gundersen, G. G. Localized stabilization of microtubules by integrin- and FAK-facilitated Rho signaling. Science 2004, 303, 836-839.
34. Xu, J.; Wang, F.; Van Keymeulen, A.; Rentel, M.; Bourne, H. R. Neutrophil microtubules suppress polarity and enhance directional migration. Proc. Natl. Acad. Sci. USA 2005, 102, 6884-6889.
35. Watabe-Uchida, M.; John, K. A.; Janas, J. A.; Newey, S. E.; Van Aelst, L. The Rac activator DOCK7 regulates neuronal polarity through local phosphorylation of stathmin/Op18. Neuron 2006, 51, 727-739.
36. Wyckoff, J. B.; Jones, J. G.; Condeelis, J. S.; Segall, J. E. A critical step in metastasis: in vivo analysis of intravasation at the primary tumor. Cancer Res. 2000, 60, 2504-2511.
37. Wang, W.; Wyckoff, J. B.; Frohlich, V. C.; Oleynikov, Y.; Huttelmaier, S.; Zavadil, J.; Cermak, L.; Bottinger, E. P.; Singer, R. H.; White, J. G.; Segall, J. E.; Condeelis, J. S. Single cell behavior in metastatic primary mammary tumors correlated with gene expression patterns revealed by molecular profiling. Cancer Res. 2002, 62, 6278-6288.
38. Itoh, K.; Yoshioka, K.; Akedo, H.; Uehata, M.; Ishizaki, T.; Narumiya, S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat. Med. 1999, 5, 221-225.
39. Takamura, M.; Sakamoto, M.; Genda, T.; Ichida, T.; Asakura, H.; Hirohashi, S. Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632. Hepatology 2001, 33, 577-581.
40. Olson, M. F. Applications for ROCK kinase inhibition. Curr. Opin. Cell Biol. 2008, 20, 242-248.
41. Asano, T.; Ikegaki, I.; Satoh, S.; Suzuki, Y.; Shibuya, M.; Takayasu, M.; Hidaka, H. Mechanism of action of a novel antivasospasm drug, HA1077. J. Pharmacol. Exp. Ther. 1987, 241, 1033-1040.
42. Suzuki, Y.; Shibuya, M.; Satoh, S.; Sugimoto, Y.; Takakura, K. A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg. Neurol. 2007, 68, 126-131.
43. Shimokawa, H.; Takeshita, A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 1767-1775.
44. Fukumoto, Y.; Mohri, M.; Inokuchi, K.; Ito, A.; Hirakawa, Y.; Masumoto, A.; Hirooka, Y.; Takeshita, A.; Shimokawa, H. Antiischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina. J. Cardiovasc. Pharmacol. 2007, 49, 117-121.
45. Noma, K.; Goto, C.; Nishioka, K.; Jitsuiki, D.; Umemura, T.; Ueda, K.; Kimura, M.; Nakagawa, K.; Oshima, T.; Chayama, K.; Yoshizumi, M.; Liao, J. K.; Higashi, Y. Roles of rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness. J. Am. Coll. Cardiol. 2007, 49, 698-705.
46. Inokuchi, K.; Ito, A.; Fukumoto, Y.; Matoba, T.; Shiose, A.; Nishida, T.; Masuda, M.; Morita, S.; Shimokawa, H. Usefulness of fasudil, a Rho-kinase inhibitor, to treat intractable severe coronary spasm after coronary artery bypass surgery. J. Cardiovasc. Pharmacol. 2004, 44, 275-277.
47. Masumoto, A.; Hirooka, Y.; Shimokawa, H.; Hironaga, K.; Setoguchi, S.; Takeshita, A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 2001, 38, 1307-1310.
48. Bussemaker, E.; Herbrig, K.; Pistrosch, F.; Palm, C.; Passauer, J. Role of rho-kinase in the regulation of vascular tone in hypertensive renal transplant recipients. Atherosclerosis 2009, 207, 567-572.
49. Shibuya, M.; Hirai, S.; Seto, M.; Satoh, S.; Ohtomo, E. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J. Neurol. Sci. 2005, 238, 31-39.
50. Liao, J. K.; Seto, M.; Noma, K. Rho kinase (ROCK) inhibitors. J. Cardiovasc. Pharmacol. 2007, 50, 17-24.
51. Chen, Y. T.; Bannister, T. D.; Weiser, A.; Griffin, E.; Lin, L.; Ruiz, C.; Cameron, M. D.; Schurer, S.; Duckett, D.; Schroter, T.; Lo-Grasso, P.; Feng, Y. Chroman-3-amides as potent Rho kinase inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 6406-6409.
52. Narumiya, S.; Tanji, M.; Ishizaki, T. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev. 2009, 28, 65-76.
53. Kume, H. RhoA/Rho-kinase as a therapeutic target in asthma. Curr. Med. Chem. 2008, 15, 2876-2885.
54. Ishikawa, Y.; Nishikimi, T.; Akimoto, K.; Ishimura, K.; Ono, H.; Matsuoka, H. Long-term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats. Hypertension 2006, 47, 1075-1083.
55. Arita, R.; Hata, Y.; Nakao, S.; Kita, T.; Miura, M.; Kawahara, S.; Zandi, S.; Almulki, L.; Tayyari, F.; Shimokawa, H.; Hafezi-Moghadam, A.; Ishibashi, T. Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage. Diabetes 2009, 58, 215-226.
56. Laschke, M. W.; Dold, S.; Jeppsson, B.; Schilling, M. K.; Menger, M. D.; Thorlacius, H. Rho-Kinase Inhibitor Attenuates Cholestasis-Induced CXC Chemokine Formation, Leukocyte Recruitment, and Hepatocellular Damage in the Liver. J. Surg. Res. 2008, [Epub Ahead of Print].
57. Tasaka, S.; Koh, H.; Yamada, W.; Shimizu, M.; Ogawa, Y.; Hasegawa, N.; Yamaguchi, K.; Ishii, Y.; Richer, S. E.; Doerschuk, C. M.; Ishizaka, A. Attenuation of endotoxin-induced acute lung injury by the Rho-associated kinase inhibitor, Y-27632. Am. J. Respir. Cell Mol. Biol. 2005, 32, 504-510.
58. Kubo, T.; Yamashita, T. Rho-ROCK inhibitors for the treatment of CNS injury. Recent Pat. CNS Drug Discov. 2007, 2, 173-179.
59. McTaggart, S. J. Isoprenylated proteins. Cell Mol. Life Sci. 2006, 63, 255-267.
60. Wiemer, A. J.; Hohl, R. J.; Wiemer, D. F. The intermediate enzymes of isoprenoid metabolism as anticancer targets. Anticancer Agents Med. Chem. 2009, 9, 526-542.
61. Zhou, Q.; Liao, J. K. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr. Pharm. Des. 2009, 15, 467-478.
62. Budzyn, K.; Marley, P. D.; Sobey, C. G. Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. Trends Pharmacol. Sci. 2006, 27, 97-104.
63. Russell, R. G.; Watts, N. B.; Ebetino, F. H.; Rogers, M. J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos. Int. 2008, 19, 733-759.
64. Drake, M. T.; Clarke, B. L.; Khosla, S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin. Proc. 2008, 83, 1032-1045.
65. Shi, J.; Wei, L. Rho kinase in the regulation of cell death and survival. Arch. Immunol. Ther. Exp. (Warsz.) 2007, 55, 61-75.
66. Imamura, F.; Mukai, M.; Ayaki, M.; Akedo, H. Y-27632, an inhibitor of rho-associated protein kinase, suppresses tumor cell invasion via regulation of focal adhesion and focal adhesion kinase. Jpn. J. Cancer Res. 2000, 91, 811-816.
67. Wicki, A.; Niggli, V. The Rho/Rho-kinase and the phosphatidylinositol 3-kinase pathways are essential for spontaneous locomotion of Walker 256 carcinosarcoma cells. Int. J. Cancer 2001, 91, 763-771.
68. Ogawa, T.; Tashiro, H.; Miyata, Y.; Ushitora, Y.; Fudaba, Y.; Kobayashi, T.; Arihiro, K.; Okajima, M.; Asahara, T. Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model. Am. J. Transplant. 2007, 7, 347-355.
69. Nakajima, M.; Katayama, K.; Tamechika, I.; Hayashi, K.; Amano, Y.; Uehata, M.; Goto, N.; Kondo, T. WF-536 inhibits metastatic invasion by enhancing the host cell barrier and inhibiting tumour cell motility. Clin. Exp. Pharmacol. Physiol 2003, 30, 457-463.
70. Torka, R.; Thuma, F.; Herzog, V.; Kirfel, G. ROCK signaling mediates the adoption of different modes of migration and invasion in human mammary epithelial tumor cells. Exp. Cell Res. 2006, 312, 3857-3871.
71. Leve, F.; de Souza, W.; Morgado-Diaz, J. A. A cross-link between protein kinase A and Rho-family GTPases signaling mediates cell-cell adhesion and actin cytoskeleton organization in epithelial cancer cells. J. Pharmacol. Exp. Ther. 2008, 327, 777-788.
72. Vishnubhotla, R.; Sun, S.; Huq, J.; Bulic, M.; Ramesh, A.; Guzman, G.; Cho, M.; Glover, S. C. ROCK-II mediates colon cancer invasion via regulation of MMP-2 and MMP-13 at the site of invadopodia as revealed by multiphoton imaging. Lab. Invest. 2007, 87, 1149-1158.
73. Xue, F.; Takahara, T.; Yata, Y.; Xia, Q.; Nonome, K.; Shinno, E.; Kanayama, M.; Takahara, S.; Sugiyama, T. Blockade of Rho/Rho-associated coiled coil-forming kinase signaling can prevent progression of hepatocellular carcinoma in matrix metalloproteinase-dependent manner. Hepatol. Res. 2008, 38, 810-817.
74. Ying, H.; Biroc, S. L.; Li, W. W.; Alicke, B.; Xuan, J. A.; Pagila, R.; Ohashi, Y.; Okada, T.; Kamata, Y.; Dinter, H. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol. Cancer Ther. 2006, 5, 2158-2164.
75. Niggli, V.; Schmid, M.; Nievergelt, A. Differential roles of Rho-kinase and myosin light chain kinase in regulating shape, adhesion, and migration of HT1080 fibrosarcoma cells. Biochem. Biophys. Res. Commun. 2006, 343, 602-608.
76. Salhia, B.; Rutten, F.; Nakada, M.; Beaudry, C.; Berens, M.; Kwan, A.; Rutka, J. T. Inhibition of Rho-kinase affects astrocytoma morphology, motility, and invasion through activation of Rac1. Cancer Res. 2005, 65, 8792-8800.
77. Swanson, K. M.; Hohl, R. J. Anti-cancer therapy: targeting the mevalonate pathway. Curr. Cancer Drug Targets 2006, 6, 15-37.
78. Rattan, R.; Giri, S.; Singh, A. K.; Singh, I. Rho/ROCK pathway as a target of tumor therapy. J. Neurosci. Res. 2006, 83, 243-255.
79. Wong, W. W.; Clendening, J. W.; Martirosyan, A.; Boutros, P. C.; Bros, C.; Khosravi, F.; Jurisica, I.; Stewart, A. K.; Bergsagel, P. L.; Penn, L. Z. Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma. Mol. Cancer Ther. 2007, 6, 1886-1897.
80. Zhong, W. B.; Liang, Y. C.; Wang, C. Y.; Chang, T. C.; Lee, W. S. Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling. Endocr. Relat. Cancer 2005, 12, 615-629.
81. Kusama, T.; Mukai, M.; Tatsuta, M.; Nakamura, H.; Inoue, M. Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho. Int. J. Oncol. 2006, 29, 217-223.
82. Nieuw Amerongen, G. P.; van Hinsbergh, V. W. Role of ROCK I/II in vascular branching. Am. J. Physiol. Heart Circ. Physiol. 2009, 296, H903-H905.
83. Yin, L.; Morishige, K.; Takahashi, T.; Hashimoto, K.; Ogata, S.; Tsutsumi, S.; Takata, K.; Ohta, T.; Kawagoe, J.; Takahashi, K.; Kurachi, H. Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Mol. Cancer Ther. 2007, 6, 1517-1525.
84. Ghosh, K.; Thodeti, C. K.; Dudley, A. C.; Mammoto, A.; Klagsbrun, M.; Ingber, D. E. Tumor-derived endothelial cells exhibit aberrant Rho-mediated mechanosensing and abnormal angiogenesis in vitro. Proc. Natl. Acad. Sci. USA 2008, 105, 11305-11310.
85. Pang, X.; Yi, T.; Yi, Z.; Cho, S. G.; Qu, W.; Pinkaew, D.; Fujise, K.; Liu, M. Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways. Cancer Res. 2009, 69, 518-525.
86. Mavria, G.; Vercoulen, Y.; Yeo, M.; Paterson, H.; Karasarides, M.; Marais, R.; Bird, D.; Marshall, C. J. ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis. Cancer Cell 2006, 9, 33-44.
87. Kroll, J.; Epting, D.; Kern, K.; Dietz, C. T.; Feng, Y.; Hammes, H. P.; Wieland, T.; Augustin, H. G. Inhibition of Rho-dependent kinases ROCK I/II activates VEGF-driven retinal neovascularization and sprouting angiogenesis. Am. J. Physiol. Heart Circ. Physiol. 2009, 296, H893-H899.
88. Burthem, J.; Rees-Unwin, K.; Mottram, R.; Adams, J.; Lucas, G. S.; Spooncer, E.; Whetton, A. D. The rho-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34(+) CML progenitor cells. Leukemia 2007, 21, 1708-1714.
89. Saarto, T.; Vehmanen, L.; Virkkunen, P.; Blomqvist, C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol. 2004, 43, 650-656.
90. Aapro, M.; Abrahamsson, P. A.; Body, J. J.; Coleman, R. E.; Colomer, R.; Costa, L.; Crino, L.; Dirix, L.; Gnant, M.; Gralow, J.; Hadji, P.; Hortobagyi, G. N.; Jonat, W.; Lipton, A.; Monnier, A.; Paterson, A. H.; Rizzoli, R.; Saad, F.; Thurlimann, B. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann. Oncol. 2008, 19, 420-432.
91. Diel, I. J.; Jaschke, A.; Solomayer, E. F.; Gollan, C.; Bastert, G.; Sohn, C.; Schuetz, F. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann. Oncol. 2008, 19, 2007-2011.
92. Kuoppala, J.; Lamminpaa, A.; Pukkala, E. Statins and cancer: A systematic review and meta-analysis. Eur. J. Cancer 2008, 44, 2122-2132.